NewAmsterdam Total Assets from 2010 to 2025

NAMS Stock

23.87 0.20 0.83%

NewAmsterdam Pharma Total Assets yearly trend continues to be comparatively stable with very little volatility. Total Assets are likely to outpace its year average in 2025. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2010-12-31

Previous Quarter

864.6 M

Current Value

907.9 M

Quarterly Volatility

314.6 M

Credit Downgrade

Yuan Drop

Covid

Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 17.7 M, Interest Income of 17.7 M or Interest Expense of 0.0, as well as many indicators such as Price To Sales Ratio of 33.94, Dividend Yield of 0.0 or PTB Ratio of 3.36. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.

Check out the analysis of NewAmsterdam Pharma Correlation against competitors.

For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.

Latest NewAmsterdam Pharma's Total Assets Growth Pattern

Below is the plot of the Total Assets of NewAmsterdam Pharma over the last few years. Total assets refers to the total amount of NewAmsterdam Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in NewAmsterdam Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. NewAmsterdam Pharma's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewAmsterdam Pharma's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 864.62 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

NewAmsterdam Total Assets Regression Statistics

	Arithmetic Mean	175,779,625
	Geometric Mean	29,661,836
	Coefficient Of Variation	179.00
	Mean Deviation	243,504,062
	Median	9,231,000
	Standard Deviation	314,637,737
	Sample Variance	98996.9T
	Range	898.6M
	R-Value	0.74
	Mean Square Error	47579.8T
	R-Squared	0.55
	Significance	0.001
	Slope	49,074,865
	Total Sum of Squares	1484953.6T

NewAmsterdam Total Assets History

	2025	907.9 M
	2024	864.6 M
	2023	347.1 M
	2022	531.6 M
	2021	59.8 M

Other Fundumenentals of NewAmsterdam Pharma

Intangibles To Total Assets

NewAmsterdam Pharma Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Good Will	Intangible Assets
Total Assets		1.0	0.86	-1.0	-0.95	0.63	0.98	1.0	-0.84	1.0	0.31	1.0	-0.8	0.31	0.73	0.73	-0.91	-0.84	-0.84
Total Stockholder Equity	1.0		0.86	-1.0	-0.94	0.63	0.98	1.0	-0.83	1.0	0.33	1.0	-0.8	0.33	0.74	0.74	-0.91	-0.83	-0.82
Net Tangible Assets	0.86	0.86		-0.87	-0.82	0.85	0.81	0.85	-0.6	0.85	0.42	0.85	-0.99	0.42	0.95	0.75	-0.87	-0.6	-0.75
Net Debt	-1.0	-1.0	-0.87		0.96	-0.65	-0.98	-1.0	0.81	-1.0	-0.3	-1.0	0.82	-0.3	-0.76	-0.73	0.93	0.81	0.86
Retained Earnings	-0.95	-0.94	-0.82	0.96		-0.61	-0.99	-0.94	0.85	-0.97	-0.04	-0.96	0.76	-0.04	-0.7	-0.57	0.87	0.85	0.96
Accounts Payable	0.63	0.63	0.85	-0.65	-0.61		0.6	0.63	-0.3	0.61	0.48	0.62	-0.89	0.48	0.84	0.85	-0.83	-0.3	-0.66
Total Liab	0.98	0.98	0.81	-0.98	-0.99	0.6		0.98	-0.87	0.99	0.14	0.99	-0.75	0.14	0.68	0.64	-0.89	-0.87	-0.91
Net Invested Capital	1.0	1.0	0.85	-1.0	-0.94	0.63	0.98		-0.84	1.0	0.33	1.0	-0.8	0.33	0.73	0.73	-0.91	-0.84	-0.82
Short Long Term Debt	-0.84	-0.83	-0.6	0.81	0.85	-0.3	-0.87	-0.84		-0.86	0.08	-0.85	0.51	0.08	-0.36	-0.37	0.58	1.0	0.74
Total Current Assets	1.0	1.0	0.85	-1.0	-0.97	0.61	0.99	1.0	-0.86		0.25	1.0	-0.79	0.25	0.72	0.69	-0.9	-0.86	-0.86
Capital Stock	0.31	0.33	0.42	-0.3	-0.04	0.48	0.14	0.33	0.08	0.25		0.27	-0.46	1.0	0.48	0.76	-0.43	0.08	0.12
Net Working Capital	1.0	1.0	0.85	-1.0	-0.96	0.62	0.99	1.0	-0.85	1.0	0.27		-0.8	0.27	0.73	0.7	-0.9	-0.85	-0.85
Short Term Debt	-0.8	-0.8	-0.99	0.82	0.76	-0.89	-0.75	-0.8	0.51	-0.79	-0.46	-0.8		-0.46	-0.97	-0.76	0.85	0.51	0.7
Common Stock	0.31	0.33	0.42	-0.3	-0.04	0.48	0.14	0.33	0.08	0.25	1.0	0.27	-0.46		0.48	0.76	-0.43	0.08	0.12
Property Plant Equipment	0.73	0.74	0.95	-0.76	-0.7	0.84	0.68	0.73	-0.36	0.72	0.48	0.73	-0.97	0.48		0.7	-0.83	-0.36	-0.65
Current Deferred Revenue	0.73	0.74	0.75	-0.73	-0.57	0.85	0.64	0.73	-0.37	0.69	0.76	0.7	-0.76	0.76	0.7		-0.86	-0.37	-0.51
Net Receivables	-0.91	-0.91	-0.87	0.93	0.87	-0.83	-0.89	-0.91	0.58	-0.9	-0.43	-0.9	0.85	-0.43	-0.83	-0.86		0.58	0.84
Good Will	-0.84	-0.83	-0.6	0.81	0.85	-0.3	-0.87	-0.84	1.0	-0.86	0.08	-0.85	0.51	0.08	-0.36	-0.37	0.58		0.74
Intangible Assets	-0.84	-0.82	-0.75	0.86	0.96	-0.66	-0.91	-0.82	0.74	-0.86	0.12	-0.85	0.7	0.12	-0.65	-0.51	0.84	0.74

Click cells to compare fundamentals

About NewAmsterdam Pharma Financial Statements

NewAmsterdam Pharma shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although NewAmsterdam Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in NewAmsterdam Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on NewAmsterdam Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

		Last Reported	Projected for Next Year
	Total Assets	864.6 M	907.9 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC